€35.94
1.37%
Xetra, Dec 23, 05:35 pm CET
ISIN
DE000BAY0017
Symbol
BAYN

Bayer Stock price

€35.94
+5.35 17.47% 1M
+9.71 36.99% 6M
+16.63 86.08% YTD
+17.05 90.26% 1Y
-12.68 26.08% 3Y
-12.24 25.40% 5Y
-80.16 69.04% 10Y
+0.28 0.79% 20Y
Xetra, Closing price Tue, Dec 23 2025
+0.49 1.37%
ISIN
DE000BAY0017
Symbol
BAYN
Industry

New AI Insights on Bayer Insights AI Insights on Bayer

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
€35.3b
Enterprise Value
€67.7b
Net debt
€32.4b
Cash
€7.2b
Shares outstanding
982.4m
Valuation (TTM | estimate)
P/E
negative | 7.5
P/S
0.8 | 0.8
EV/Sales
1.5 | 1.5
EV/FCF
17.2
P/B
1.2
Dividends
DPS
€0.11
Yield 1Y | 5Y
0.3% | 2.7%
Growth 1Y | 5Y
0.0% | -47.7%
Payout 1Y | 3Y
-4.2% | -191.2%
Increased
0 Years
Financials (TTM | estimate)
Revenue
€45.9b | €46.5b
EBITDA
€6.1b | €9.6b
EBIT
€1.9b | €6.3b
Net Income
€-198.0m | €4.7b
Free Cash Flow
€3.9b
Growth (TTM | estimate)
Revenue
-1.9% | -0.2%
EBITDA
-35.0% | -24.9%
EBIT
-2.8% | 57.1%
Net Income
77.5% | 284.4%
Free Cash Flow
-25.8%
Margin (TTM | estimate)
Gross
56.4%
EBITDA
13.4% | 20.6%
EBIT
4.2%
Net
-0.4% | 10.1%
Free Cash Flow
8.6%
Financial Health
Equity Ratio
28.8%
Return on Equity
-8.0%
ROCE
2.6%
ROIC
1.9%
Debt/Equity
1.3
More
EPS
€-0.2
FCF per Share
€4.0
Short interest
-
Employees
91k
Rev per Employee
€510.0k
Show more

Create a Free Account to create an Bayer alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Bayer Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Bayer forecast:

12x Buy
43%
15x Hold
54%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Bayer forecast:

Buy
43%
Hold
54%
Sell
4%

Financial data from Bayer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
45,866 45,866
2% 2%
100%
- Direct Costs 20,019 20,019
0% 0%
44%
25,847 25,847
3% 3%
56%
- Selling and Administrative Expenses 14,992 14,992
1% 1%
33%
- Research and Development Expense 6,089 6,089
10% 10%
13%
6,146 6,146
35% 35%
13%
- Depreciation and Amortization 4,218 4,218
44% 44%
9%
EBIT (Operating Income) EBIT 1,928 1,928
3% 3%
4%
Net Profit -198 -198
78% 78%
0%

In millions EUR.

Don't miss a Thing! We will send you all news about Bayer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bayer Stock News

Positive
Seeking Alpha
14 days ago
Bayer Aktiengesellschaft remains deeply undervalued despite ongoing operational and litigation headwinds, supporting a bullish stance. Q3/25 results were weak, but technicals and intrinsic value calculations indicate potential upside, especially if glyphosate litigation abates. Trump administration support for Supreme Court review of glyphosate cases could materially reduce litigation provision...
Neutral
Business Wire
23 days ago
BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, pl...
More Bayer News

Company Profile

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Head office Germany
CEO William Anderson
Employees 90,587
Founded 1863
Website www.bayer.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today